CALCIUM ACETATE | A077728 | HIKMA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lupin Pharmaceuticals, Inc. - Citizen Petition FDA-2013-P-0040 · 3 docket documents Lupin Pharmaceuticals, Inc. filed this citizen petition pursuant to 21 CFR 10.30 and 21 CFR 314.94 requesting that the FDA amend the Orange Book to designate Roxane's Calcium Acetate Capsules as a second reference listed drug for Calcium Acetate Capsules, citing that the current reference listed dru | Other | 2013-01-07 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1733
per ea
Lowest NADAC/Unit
$0.1733
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00904711906CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
| 00904711961CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
| 00054008813CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
| 00054008826CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
| 68084047901CALCIUM ACETATE 667 MG CAPSULE | $0.1733 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.